Alkermes Director Shane Cooke Sells $36.1M in ALKS Stock — Exits to Zero Shares
Alkermes director Shane Cooke has sold $36.1M in ALKS stock across 306 transactions, completing a full exit with zero shares remaining after a February 2026 exercise-and-sell.
Shane Cooke, a director at Alkermes (ALKS), has sold $36.1 million in company stock across 306 transactions — and his final February 2026 trade left him with zero shares.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $36.1M |
| Career Buy Value | $229K |
| Total Transactions | 306 |
| Last Transaction | 2026-02-02 |
| Shares Remaining | 0 |
Recent Activity
| Date | Type | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2026-02-02 | Sell | 32,113 | $34.7796 | $1.1M |
| 2026-02-02 | Sell | 29,087 | $34.3382 | $999K |
| 2025-05-31 | Exercise | 8,013 | N/A | $0 |
On February 2, 2026, Cooke exercised 61,200 options at $31.64 and immediately sold all shares in two blocks at $34.34–$34.78, netting approximately $2.1M. This final transaction brought his holdings to exactly zero.
What It Means
Cooke served as a longtime director at the Dublin-based biopharmaceutical company, which specializes in neuroscience and oncology treatments. His $36.1M in career sales against just $229K in purchases reveals a 158:1 sell-to-buy ratio. The complete exit — down to zero shares — is particularly striking for a board member.
A director voluntarily holding zero shares raises governance questions. While many board exits are planned well in advance, the optics for ALKS shareholders are unfavorable. Alkermes has seen steady revenue growth from its schizophrenia drug Lybalvi, but Cooke's total divestiture suggests his investment thesis has concluded.
What to Watch
- Whether Cooke remains on the Alkermes board with zero equity
- Other ALKS insider activity — is Cooke an outlier or part of a trend?
- Alkermes pipeline catalysts and Lybalvi prescription growth
- New board member appointments or equity grant cycles
Related Research
Explore all researchAmeriprise Financial's 11,224-position portfolio has the lowest top-5 concentration of any mega-filer at 14.8%. Netflix shares surged 943%, confirming an institutional consensus trade across $2.7 trillion in combined AUM. Salesforce built 82%.
Mar 6, 2026
Britain's largest asset manager holds NVIDIA at $32B and Apple at $30B in an unusually close #1/#2 race. AUM crashed $102B between Q3 and Q4 2024, then recovered. Netflix shares surged 916% — the fourth mega-filer to make this trade in Q4.
Mar 6, 2026
Canada's largest bank filed a U.S. 13F with 29,036 positions, three S&P 500 ETFs in its top 5, $12.5B of its own stock (RY), and $11.9B of competitor Toronto-Dominion. Netflix shares surged 893% in one quarter.
Mar 6, 2026
While most mega-filers lead with NVIDIA, Capital International Investors bets biggest on Broadcom at 7.7% of portfolio. They also increased Netflix shares by 710% in Q4 2025, added $3.4B in TotalEnergies, and exited Disney entirely.
Mar 6, 2026
The second Capital Group division to file a massive Netflix build in Q4 2025. Capital Research Global also doubled its Applied Materials position, holds $26B in Eli Lilly, and opened a $1B position in MicroStrategy — the Bitcoin proxy.
Mar 6, 2026